SEC14L5 Inhibitors
SEC14L5 inhibitors are a class of chemical compounds that target the SEC14-like lipid transfer protein 5 (SEC14L5), which belongs to the broader SEC14 family of proteins. These proteins are characterized by their ability to transfer phospholipids between membranes, playing a crucial role in maintaining the integrity and functionality of cellular membranes. SEC14-like proteins are known for their ability to regulate lipid metabolism and trafficking within the cell. The SEC14L5 variant, in particular, is involved in the regulation of phosphatidylinositol (PI) and phosphatidylcholine (PC) transport, which are essential for various cellular processes including membrane signaling and lipid homeostasis. By inhibiting SEC14L5, compounds within this chemical class disrupt the lipid transfer activity that this protein facilitates, leading to alterations in intracellular lipid distribution and signaling dynamics.
The structural diversity of SEC14L5 inhibitors reflects their specificity in targeting the unique lipid-binding pocket within the SEC14L5 domain. These inhibitors typically interact with key residues responsible for lipid recognition and binding, thereby preventing the normal lipid exchange process. The mode of inhibition can involve either competitive binding to the lipid-binding site or allosteric modulation, whereby conformational changes are induced in the protein to hinder its activity. Structural studies of SEC14L5 have revealed potential binding sites that make it amenable to small-molecule inhibition, allowing for the development of inhibitors that can selectively block this protein's function without affecting other members of the SEC14 family. This specificity is particularly important, as it minimizes off-target effects on other SEC14-related lipid transfer proteins, which might play distinct roles in cellular lipid management. Through their capacity to interfere with lipid transfer, SEC14L5 inhibitors provide a valuable tool for studying lipid dynamics and membrane biology in various cellular contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Activates peroxisome proliferator-activated receptor alpha (PPARα), influencing lipid metabolism and potentially affecting SEC14L5-related pathways. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Activates PPARγ, modulating lipid and glucose metabolism, which could indirectly affect SEC14L5 activity. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Inhibits HMG-CoA reductase, affecting cholesterol biosynthesis and potentially impacting lipid profiles relevant to SEC14L5. | ||||||
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
Inhibits gastric and pancreatic lipases, decreasing fat absorption and potentially altering lipid availability for SEC14L5. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
Inhibits fatty acid synthase, potentially impacting lipid synthesis and availability for SEC14L5. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
Inhibits long-chain acyl-CoA synthetase, affecting fatty acid metabolism and potentially SEC14L5's lipid interactions. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi apparatus structure and function, affecting vesicle trafficking pathways that may involve SEC14L5. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
A polyether antibiotic that alters ion transport and vesicle trafficking, potentially impacting SEC14L5 activity. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
A PPARα agonist, similar to fenofibrate, modulating lipid metabolism pathways that could intersect with SEC14L5's role. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Another HMG-CoA reductase inhibitor, similar to lovastatin, potentially influencing lipid metabolism affecting SEC14L5. | ||||||